## **Eiger BioPharmaceuticals to Present at the 2016 Wedbush PacGrow Healthcare Conference on August 17th**

PALO ALTO, Calif., August 8, 2016, /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 3:05 pm ET at Le Parker Meridien Hotel in New York City.

A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at <u>www.eigerbio.com</u>, under the "Investors" tab. A replay of the webcast will be available approximately one hour following the completion of the live event.

## **About Eiger**

Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The Company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit <u>www.eigerbio.com</u>.



SOURCE Eiger BioPharmaceuticals, Inc.

Investors: Jim Shaffer, Eiger Bio, Inc., 919-345-4256, jshaffer@eigerbio.com